Loading
NASDAQHealthcareBiotechnology
Latest quote
$12.70
+$0.11 · +0.87%
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Latest quote
$12.70
+$0.11 · +0.87%
After-hours
$12.70
$0.00 · 0.00%
Oct 8, 4:43 PM ET
Regular session · ET · Market data may be delayed.
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Day range
Current $12.70
52-week range
Current $12.70
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
64
Undervalued
Sentiment
74
Bullish
Risk
62
High Risk
Momentum
66
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Day range
Current $12.70
52-week range
Current $12.70
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 85.21M USD | 37K USD | 20.72M USD | 3.13M USD | 18.04M USD |
| Cost of goods sold | 7.63M USD | 141.3M USD | 97.1M USD | 80.25M USD | 61.36M USD |
| Gross profit | 77.58M USD | −141.26M USD | −76.37M USD | −77.12M USD | −43.32M USD |
| Research and development | 195.7M USD | 141.3M USD | 97.1M USD | 80.25M USD | 61.36M USD |
| Selling, general, and administrative | 49.06M USD | 46.58M USD | 36.49M USD | 32.91M USD | 28.01M USD |
| Operating expenses | 237.13M USD | 46.58M USD | 36.49M USD | 32.91M USD | 28.01M USD |
| Interest income | 19.48M USD | 27.05M USD | 12.21M USD | 2.57M USD | 137K USD |
| Depreciation and amortization | 7.63M USD | 6.71M USD | 5.75M USD | 3.88M USD | 3.02M USD |
| Operating income | −159.55M USD | −187.84M USD | −112.87M USD | −110.03M USD | −71.33M USD |
| Net income | −140.11M USD | −160.87M USD | −100.84M USD | −107.49M USD | −71.32M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$29.67
133.62% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI22.41M0.00%2.3T USD0.03%$379.56-0.39%
State Street SPDR S&P Biotech ETFXBI15.2M0.15%10.08B USD0.35%$149.29-0.63%
iShares Russell 2000 ETFIWM15.15M0.02%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF6.59M0.01%95.4B USD0.05%$233.13-0.15%
iShares Biotechnology ETFIBB4.77M0.05%10.4B USD0.44%$200.48-1.41%
Dimensional - US Small Cap ETFDFAS3.86M0.01%33.66B USD0.31%$78.10+0.23%
Vanguard Russell 2000 ETFVTWO3.72M0.02%18B USD0.06%$112.1-0.10%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP3.54M0.13%2.69B USD0.20%$65.61-1.19%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
